Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNPX Genprex	$0.17 +1.2%	$0.24	$0.14 ▼ $3.97	$5.85M	-0.53	3.48 million shs	3.94 million shs
NBY NovaBay Pharmaceuticals	$1.65 +6.5%	$0.67	$0.44 ▼ $1.90	$9.61M	0.4	2.33 million shs	5.60 million shs
NSPX Inspyr Therapeutics		$0.00	$0.00 ▼ $0.07	$1.47M	-17.33	13.19 million shs	29.64 million shs
PPBT Purple Biotech	$2.27 +2.3%	$2.36	$2.00 ▼ $13.95	$5.88M	0.49	86,050 shs	28,562 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNPX Genprex	+1.89%	+6.02%	-34.18%	-48.14%	-75.41%
NBY NovaBay Pharmaceuticals	+72.41%	+50.49%	+140.83%	+180.54%	+205.66%
NSPX Inspyr Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PPBT Purple Biotech	-1.77%	+0.05%	-1.33%	-7.11%	+221,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNPX Genprex	1.8588 of 5 stars	0.0	3.0	0.0	4.7	3.8	0.0	0.6
NBY NovaBay Pharmaceuticals	0.7483 of 5 stars	1.5	0.0	0.0	0.0	3.1	0.0	1.3
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PPBT Purple Biotech	1.8439 of 5 stars	3.5	2.0	0.0	0.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNPX Genprex	0.00	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	3.00	Buy	$0.85	-48.48% Downside
NSPX Inspyr Therapeutics	0.00	N/A	N/A	N/A
PPBT Purple Biotech	3.00	Buy	$33.00	1,353.74% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNPX Genprex	N/A	N/A	N/A	N/A	$0.04 per share	N/A
NBY NovaBay Pharmaceuticals	$9.78M	0.98	N/A	N/A	$4.25 per share	0.39
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A
PPBT Purple Biotech	N/A	N/A	N/A	N/A	$12.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNPX Genprex	-$21.11M	N/A	0.00	N/A	N/A	N/A	-809.27%	-386.95%	11/11/2025 (Estimated)
NBY NovaBay Pharmaceuticals	-$9.64M	-$53.72	N/A	N/A	N/A	-102.72%	-7,293.78%	-158.41%	N/A
NSPX Inspyr Therapeutics	-$6.30M	N/A	0.00	N/A	N/A	N/A	N/A	-1,354.49%	N/A
PPBT Purple Biotech	-$7.24M	-$0.42	N/A	N/A	N/A	N/A	-14.00%	-12.52%	N/A

Latest NSPX, PPBT, GNPX, and NBY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	GNPX Genprex	-$0.71	-$0.17	+$0.54	-$0.17	N/A	N/A
8/6/2025	Q2 2025	PPBT Purple Biotech	-$0.21	-$0.40	-$0.19	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNPX Genprex	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A	N/A
PPBT Purple Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNPX Genprex	N/A	0.84	0.84
NBY NovaBay Pharmaceuticals	N/A	1.15	0.91
NSPX Inspyr Therapeutics	N/A	0.09	0.09
PPBT Purple Biotech	N/A	2.88	2.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNPX Genprex	14.05%
NBY NovaBay Pharmaceuticals	23.25%
NSPX Inspyr Therapeutics	0.02%
PPBT Purple Biotech	9.64%

Insider Ownership

Company	Insider Ownership
GNPX Genprex	0.44%
NBY NovaBay Pharmaceuticals	0.10%
NSPX Inspyr Therapeutics	0.02%
PPBT Purple Biotech	2.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNPX Genprex	20	33.47 million	33.32 million	No Data
NBY NovaBay Pharmaceuticals	30	5.82 million	4.88 million	Not Optionable
NSPX Inspyr Therapeutics	1	543.15 million	N/A	Not Optionable
PPBT Purple Biotech	20	2.59 million	2.51 million	Optionable

NSPX, PPBT, GNPX, and NBY Headlines

Recent News About These Companies

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

August 27 at 7:00 AM | globenewswire.com

Purple Biotech Reports Second Quarter 2025 Financial Results

August 6, 2025 | globenewswire.com

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

July 23, 2025 | globenewswire.com

Purple Biotech Stock Price History - Investing.com

July 8, 2025 | investing.com

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

June 23, 2025 | globenewswire.com

Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer

June 17, 2025 | finance.yahoo.com

Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

June 4, 2025 | finance.yahoo.com

H.C. Wainwright Raises Purple Biotech (PPBT) Price Target, Reiterates Buy Rating

June 1, 2025 | msn.com

Purple Biotech Ltd.: Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025 | finanznachrichten.de

Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025 | globenewswire.com

Purple Biotech Appoints Shai Lankry as Chief Financial Officer to Drive Strategic Growth and Financial Excellence

May 13, 2025 | nasdaq.com

Purple Biotech appoints Shai Lankry as new CFO

May 13, 2025 | investing.com

Purple Biotech Ltd.: Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025 | finanznachrichten.de

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025 | globenewswire.com

Purple Biotech Unveils Promising Phase 2 Results for CM24 in Pancreatic Cancer

April 30, 2025 | tipranks.com

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

April 28, 2025 | globenewswire.com

Purple Biotech announces publication of study on potential of NT219

April 17, 2025 | markets.businessinsider.com

Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting

March 28, 2025 | finance.yahoo.com

Purple Biotech Unveils Updated Oncology Pipeline Progress

March 18, 2025 | tipranks.com

Purple Biotech Reports Positive Clinical Trial Results for CM24 and NT219, Advancing to Phase 2 Studies

March 12, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NSPX, PPBT, GNPX, and NBY Company Descriptions

Genprex NASDAQ:GNPX

$0.17 +0.00 (+1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$0.17 0.00 (-0.40%)

As of 05:48 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

NovaBay Pharmaceuticals NYSE:NBY

$1.65 +0.10 (+6.45%)

As of 04:00 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Inspyr Therapeutics OTCMKTS:NSPX

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

Purple Biotech NASDAQ:PPBT

$2.27 +0.05 (+2.25%)

Closing price 03:58 PM Eastern

Extended Trading

$2.23 -0.04 (-1.59%)

As of 04:39 PM Eastern

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time